US EditionCAR-T Cell Therapy Is Likely Curative for One in Three Patients with Advanced Myeloma
Summary by medicinsketidsskrifter.dk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
HEMATOLOGICAL JOURNAL CAR-T cell therapy likely cures one in three patients with advanced bone marrow cancer More than five years after the end of treatment, 33 percent of patients enrolled in the phase Ib/2 CARTITUDE-1 trial remained in remission without further treatment. This is shown by long-term data from the study, which for the first time suggests that the CAR-T cell therapy Carvykti (ciltacabtagene autoleucel, cilta-cel) is a curative st…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
